PLC Medical Systems has been granted a new method patent by the US Patent and Trademark Office, titled, 'Patient Hydration Method.'
The patent claims cover the use of RenalGuard Therapy and the RenalGuard device to protect patients' kidneys from therapeutic agents that are potentially harmful.
RenalGuard technology is used to minimize the risk of Acute Kidney Injury (AKI) from exposure to contrast agents which particularly lead to Contrast-Induced Acute Kidney Injury or CI-AKI, while the RenalGuard therapy rapidly eliminates contrast dyes that are toxic to patients with impaired kidney function, thereby forbidding the CI-AKI occurrence in at-risk patients.
PLC Medical Marketing and Engineering director Andrew Halpert said, "We intend to continue building our patent position to enhance the value of our RenalGuard technology as a crucial therapy to reduce the risk of damage to patients' kidneys from a variety of potentially toxic agents."
